Skip to main content

Advertisement

SpringerLink
Log in

Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease

  • Pharmacoepidemiology and Prescription
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Aim. Statins have been shown to significantly reduce morbidity and mortality both in patients with coronary artery disease and in those with dyslipidemia when they are taken regularly. Middle-aged patients have the highest level of forecasting benefit, and little is known about the persistence rate of these therapies in a real-life setting.Objective. To evaluate the persistence rate of middle-aged patients initiating statin therapy as well as its relation to patients’ demographic and clinical characteristics.Methods. A cohort of 25,733 patients was reconstructed from prescription data recorded in the Régie de l’assurance maladie du Québec administrative database. All patients aged 50–64 years old who received at least one statin prescription between January 1, 1998 and December 31, 2000 for a new intention of treatment for dyslipidemia were included in the cohort and followed up until June 30, 2001. The date of the first prescription of statin was defined as the index date. The cumulative persistence rate was estimated using a Kaplan-Meier analysis. Cox regression models were used to estimate the rate ratio of ceasing statins after adjustment. Results. Mean age of patients initiating statin agents was 58 years; 39%were male, 24% received social assistance, 19% had diabetes, 30% had hypertension and 11% had a respiratory disease at cohort entry. Persistence with statin therapy fell to 67% in the first 6 months after treatment and continued to decline over the next 3 years to 39%. At 3 years, persistence varied significantly with statin agents. After controlling for individual patients’ demographic and clinical characteristics, we found that patients who were prescribed fluvastatin, lovastatin and atorvastatin had a higher rate of cessation than those on simvastatin and pravastatin. The adjusted rate ratio of ceasing statin agents in patients with other risk factors of cardiovascular disease, such as diabetes (HR: 0.78; 0.75–0.82) or hypertension (HR: 0.72; 0.69–0.74), demonstrated a lower cessation rate. We observed lower persistence in patients who used the greatest number of pharmacies and prescribing physicians.Conclusion. This analysis indicates that barriers to persistence occur early in the therapeutic course. Overall persistence with statins is low, particularly among patients with few other cardiovascular risk factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Scandinavian Simvastatin Survival Study Group (1994) Ramdomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383–1389

    PubMed  Google Scholar 

  2. Sacks FM, Pfeffer MA, Moye LA et al (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001–1009

    Article  PubMed  CAS  Google Scholar 

  3. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349–1357

    Article  PubMed  Google Scholar 

  4. Downs JR, Clearfield M, Weis S et al (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 279:1615–1622

    Article  PubMed  CAS  Google Scholar 

  5. Sheperd J, Cobbe SM, Ford I et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study group. N Engl J Med 333:1301–1307

    Article  PubMed  Google Scholar 

  6. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals. Lancet 360:7–22

    Article  PubMed  Google Scholar 

  7. Severs PS, Dahlof B, Poulter NR et al. (ASCOT investigators) (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 361:1149–1158

    Article  PubMed  CAS  Google Scholar 

  8. Genest J, Frohlich J, Fodor G, McPherson R (the Working Group on Hypercholesterolemia and other Dyslipidemias) (2003) Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. Can Med Assoc J 169:921–924

    Google Scholar 

  9. Andrade SE, Walker AM, Gottlieb LK, et al. (1995) Discontinuation of antihyperlipidemic drugs—do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 332:1125–1131

    Article  PubMed  CAS  Google Scholar 

  10. Simons LA, Levis G, Simons J (1996) Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 164:208–211

    PubMed  CAS  Google Scholar 

  11. Avorn J, Monette J, Lacour A et al. (1998) Persistence of use of lipid-lowering medications: a cross-national study. JAMA 279:1458–1462

    Article  PubMed  CAS  Google Scholar 

  12. Eriksson M, Hadell K, Holme I et al. (1998) Adherence with and efficacy of treatment with pravastatin and cholestryramine: a randomized study on lipid lowering in primary care. J Intern Med 243:373–380

    Article  PubMed  CAS  Google Scholar 

  13. Jackevicius CA, Mamdani M, Tu JV (2002) Adherence with statin in elderly patients with and without acute coronary syndromes. JAMA 288:462–467

    Article  PubMed  Google Scholar 

  14. Benner JS, Glynn RJ, Mogun H et al (2002) Long-term persistence in use of statin therapy in elderly patients. JAMA 288:455–461

    Article  PubMed  Google Scholar 

  15. Larsen J, Andersen Morten, Kragstrup J et al. (2002) High persistence of statin use in a Danish population: compliance study 1993–1998. Br J Clin Pharmacol 53:375–378

    Article  PubMed  Google Scholar 

  16. World Health Organization (1977) International classification of diseases. Manual of the international statistical classification of diseases, injuries, and cause of death, 9th revision. Publication no. PHS 80-1260. World Health Organization, Geneva, Switzerland

  17. Statistics Canada Health Division (1986) Canadian classification of diagnostic, therapeutic, and surgical procedures, 2nd edn. Supply and Services, Ottawa, Ontario, Canada

  18. Régie de l’assurance maladie du Québec (1997) Health Ministry, Government of Quebec, Quebec: Régie de l’assurance maladie du Québec

  19. Moride Y, Abenhaim L (1994) The depletion of susceptible effects in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 47:731–737

    Article  PubMed  CAS  Google Scholar 

  20. Tamblyn R, Lavoie G, Petrella L et al. (1995) The use of prescription claims database in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 48:999–1009

    Article  PubMed  CAS  Google Scholar 

  21. Wang PS, Bohn RL, Knight E et al (2002) Noncompliance with antihypertensive medications. The impact of depressive symptoms and psychosocial factors. J Gen Intern Med 17:504–511

    Article  PubMed  Google Scholar 

  22. Perreault S, Blais L, Boucher MH, Lamarre D, Berbiche D, Lalonde L, Laurier C, Collin J, St-Maurice F (2004) Persistence and determinants of statins among middle-aged patients with and without cardiovascular disease. Pharmacoepidemiol Drug Saf 13:S56

    Google Scholar 

  23. Di Matteo MR, Lepper HS, Croghan TW (2000) Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effect of anxiety and depression on patient adherence. Arch Intern Med 160:2101–2107

    Article  PubMed  CAS  Google Scholar 

  24. Kalbfleisch JP, Prentice RL (eds) (1980) The statistical analysis of failure time data. Wiley, New York

    Google Scholar 

  25. Greene WH (1997) Econometric analysis, 3rd edn. Prentice-Hall, Upper Saddle River, N.J., pp 552

    Google Scholar 

  26. Belsley DA, Kuy E, Welsch RE (1981) Regression diagnostics: identifying influential data and sources of collinearity. Wiley, New York

    Google Scholar 

  27. Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stoke: systematic review and metaanalysis. Br Med J 326:1423–1429

    Article  CAS  Google Scholar 

  28. Perreault S, Levinton C, Le Lorier J (2000) Efficacy and cost of HMG-CoA reductase inhibitors in the treatment of patients with primary hyperlipidemia. Can J Clin Pharmacol 7:144–154

    PubMed  CAS  Google Scholar 

  29. Ballantyne CM, Corsini A, Davidson MH et al (2003) Risk of myopathy with statin therapy in high-risk patients. Arch Intern Med 163:553–564

    Article  PubMed  CAS  Google Scholar 

  30. Perreault S, Hamilton V, Lavoie F, Grover S (1998) Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost-effective? Arch Intern Med 158:375–381

    Article  PubMed  CAS  Google Scholar 

  31. Perreault S, Dorais M, Coupal L, Paradis G, Joffres MR, Grover SA (1999) Impact of treating hyperlipidemia or hypertension to reduce the risk of death from coronary disease. Can Med Assoc J 160:1449–1455

    CAS  Google Scholar 

  32. Mc Donald HP, Garg AX, Haynes RB (2002) Interventions to enhance patient adherence to medication prescriptions. JAMA 288:2868–2879

    Article  PubMed  Google Scholar 

  33. Paganini-Hill A, Ross RK (1982) Reliability of recall of drug usage and other health-related information. Am J Epidemiol 116:114–122

    PubMed  CAS  Google Scholar 

  34. Rothman KJ, Greenland S (1998) Precision and validity in epidemiologic studies. Modern epidemiology. Lippincott-Raven, Philadelphia, pp 115–134

    Google Scholar 

  35. Tilley BC, Barnes AB, Bergstralh E, Labarthe D, Noller KL, Colton T et al (1985) A comparison of pregnancy history recall and medical records. Implications for retrospective studies. Am J Epidemiol 121:269–281

    CAS  Google Scholar 

  36. Van den Brandt PA, Petri H, Dorant E, Goldbohm RA, Van de CS (1991) Comparison of questionnaire information and pharmacy data on drug use. Pharm Weekbl 13:91–96

    CAS  Google Scholar 

  37. West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A (1995) Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 142:1103–1112

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the Social Sciences and Humanities Research Council of Canada (CRSH). Sylvie Perreault PhD and Lyne Lalonde are research scholars receiving financial support from the Fonds de la recherche en santé du Québec. Lucie Blais and Johanne Collin are research scholars receiving financial support from the Canadian Institutes of Health Research and CRSH, respectively.

Author information

Authors and Affiliations

  1. Faculty of Pharmacy, University of Montreal, P.O. Box 6128, Centre-Ville Station, Montreal, Quebec, Canada, H3C 3J7

    Sylvie Perreault, Lucie Blais, Alice Dragomir, Marie-Hèlène Bouchard, Lyne Lalonde, Claudine Laurier & Johanne Collin

Authors
  1. Sylvie Perreault
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lucie Blais
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alice Dragomir
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marie-Hèlène Bouchard
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lyne Lalonde
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Claudine Laurier
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Johanne Collin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sylvie Perreault.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perreault, S., Blais, L., Dragomir, A. et al. Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol 61, 667–674 (2005). https://doi.org/10.1007/s00228-005-0980-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-005-0980-z

Keywords

Search

Navigation